SG10201707267RA - Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use - Google Patents

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Info

Publication number: SG10201707267RA
Authority: SG; Singapore
Prior art keywords: regions; methods; polypeptides containing; myostatin antibodies; containing variant
Prior art date: 2015-12-18

Application number

SG10201707267RA

Inventor

Taichi Kuramochi

Tomoyuki Igawa

Hitoshi Katada

Yuji Hori

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-18

Filing date

2016-12-16

Publication date

2017-10-30

2016-12-16 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2017-10-30 Publication of SG10201707267RA publication Critical patent/SG10201707267RA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201707267RA 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use SG10201707267RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2015247070		2015-12-18

Publications (1)

Publication Number	Publication Date
SG10201707267RA true SG10201707267RA (en)	2017-10-30

Family

ID=59011957

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201707267RA SG10201707267RA (en)	2015-12-18	2016-12-16	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG11201610812WA SG11201610812WA (en)	2015-12-18	2016-12-16	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201610812WA SG11201610812WA (en)	2015-12-18	2016-12-16	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Country Status (16)

Country	Link
EP (1)	EP3390443A4 (en)
JP (4)	JP6142069B1 (en)
KR (4)	KR20240058997A (en)
CN (2)	CN108473562B (en)
AR (1)	AR107078A1 (en)
AU (1)	AU2016372934B2 (en)
BR (1)	BR112018011073A2 (en)
CA (1)	CA3002422C (en)
EA (1)	EA201891420A1 (en)
HK (1)	HK1254755A1 (en)
MX (1)	MX2018007145A (en)
MY (1)	MY189425A (en)
PH (1)	PH12018501280A1 (en)
SG (2)	SG10201707267RA (en)
TW (3)	TW202231662A (en)
WO (1)	WO2017104783A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4001409A1 (en)	2006-03-31	2022-05-25	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3521311A1 (en)	2008-04-11	2019-08-07	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2819356C (en)	2010-11-30	2023-01-24	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2013268418B2 (en)	2012-05-30	2017-12-07	Chugai Seiyaku Kabushiki Kaisha	Target-tissue-specific antigen-binding molecule
KR20230110836A (en)	2012-08-24	2023-07-25	추가이 세이야쿠 가부시키가이샤	FcγRIIb-specific Fc region variant
US11236168B2 (en)	2012-08-24	2022-02-01	Chugai Seiyaku Kabushiki Kaisha	Mouse FcγammaRII-specific Fc antibody
EP2982689B1 (en)	2013-04-02	2020-08-26	Chugai Seiyaku Kabushiki Kaisha	Fc region variant
WO2015083764A1 (en)	2013-12-04	2015-06-11	中外製薬株式会社	Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
NZ730607A (en)	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (en)	2015-02-05	2019-01-31	Чугаи Сейяку Кабусики Кайся	ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS
SG10201707267RA (en) *	2015-12-18	2017-10-30	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP7141336B2 (en)	2015-12-25	2022-09-22	中外製薬株式会社	Anti-myostatin antibodies and methods of use
KR102306744B1 (en) *	2016-06-17	2021-09-28	추가이 세이야쿠 가부시키가이샤	Anti-myostatin antibodies and methods of use
CN109689099B (en)	2016-08-05	2023-02-28	中外制药株式会社	Composition for preventing or treating IL-8-related diseases
MX2019010028A (en)	2017-02-28	2019-10-14	Seattle Genetics Inc	Cysteine mutated antibodies for conjugation.
AU2019318031A1 (en)	2018-08-10	2021-02-25	Chugai Seiyaku Kabushiki Kaisha	Anti-CD137 antigen-binding molecule and utilization thereof
KR20210149779A (en)	2019-04-10	2021-12-09	추가이 세이야쿠 가부시키가이샤	Purification method of Fc region modified antibody
KR20220093103A (en) *	2019-09-13	2022-07-05	어드메어 테라퓨틱스 소사이어티	Anti-oncolytic virus antigen antibody and method of use thereof
RU2750267C1 (en) *	2020-02-07	2021-06-25	Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ»	Recombinant growth differentiation factor 11 (gdf11), a method for its production, an injectable drug for increasing the muscle mass of mammals and poultry as well as a method of using the drug
TW202144395A (en)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2023057404A1 (en)	2021-10-06	2023-04-13	F. Hoffmann-La Roche Ag	Novel combined administration
WO2023187022A1 (en)	2022-04-01	2023-10-05	F. Hoffmann-La Roche Ag	New treatment for facioscapulohumeral muscular dystrophy (fshd)
KR20230156844A (en)	2022-05-02	2023-11-14	노보 노르디스크 에이/에스	Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutabeous administration
WO2024081932A1 (en)	2022-10-14	2024-04-18	Genentech, Inc.	Methods for treating spinal muscular atrophy
CN116990528B (en) *	2023-09-27	2024-02-06	成都华西海圻医药科技有限公司	Analysis method for rapidly determining anti-CD40 monoclonal antibody based on Gyrolab platform

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7320789B2 (en) *	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) *	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
ES2629397T3 (en) *	2004-09-24	2017-08-09	Amgen Inc.	Modified Fc molecules
US8008453B2 (en) *	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
JP5058261B2 (en) *	2006-09-05	2012-10-24	イーライリリーアンドカンパニー	Anti-myostatin antibody
PE20091163A1 (en) *	2007-11-01	2009-08-09	Wyeth Corp	ANTIBODIES FOR GDF8
EP3521311A1 (en)	2008-04-11	2019-08-07	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AR074777A1 (en) *	2008-12-19	2011-02-09	Glaxo Group Ltd	PROTEINS OF UNION TO ANTIGEN
BR112012022917A2 (en) *	2010-03-11	2017-01-10	Pfizer	ph-dependent antigen binding antibodies
UY33421A (en) *	2010-06-03	2011-12-30	Glaxo Wellcome House	HUMANIZED ANTIGEN UNION PROTEINS
RS57414B1 (en) *	2012-03-16	2018-09-28	Regeneron Pharma	Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI619729B (en) *	2012-04-02	2018-04-01	再生元醫藥公司	Anti-hla-b*27 antibodies and uses thereof
KR20150041662A (en) *	2012-08-13	2015-04-16	리제너론 파아마슈티컬스, 인크.	Anti-pcsk9 antibodies with ph-dependent binding characteristics
KR20230110836A (en) *	2012-08-24	2023-07-25	추가이 세이야쿠 가부시키가이샤	FcγRIIb-specific Fc region variant
CA2911514A1 (en) *	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
CN105960414A (en) *	2013-08-14	2016-09-21	诺华股份有限公司	Methods of treating sporadic inclusion body myositis
CA3005158A1 (en) *	2014-11-06	2016-05-12	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073906A2 (en) *	2014-11-06	2016-05-12	Scholar Rock, Inc.	Transforming growth factor-related immunoassays
NZ730607A (en) *	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201707267RA (en) *	2015-12-18	2017-10-30	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

2016
- 2016-12-16 SG SG10201707267RA patent/SG10201707267RA/en unknown
- 2016-12-16 WO PCT/JP2016/087487 patent/WO2017104783A1/en active Application Filing
- 2016-12-16 KR KR1020247013912A patent/KR20240058997A/en active Search and Examination
- 2016-12-16 MY MYPI2018702306A patent/MY189425A/en unknown
- 2016-12-16 KR KR1020187001235A patent/KR102501335B1/en active IP Right Grant
- 2016-12-16 CA CA3002422A patent/CA3002422C/en active Active
- 2016-12-16 BR BR112018011073A patent/BR112018011073A2/en active Search and Examination
- 2016-12-16 SG SG11201610812WA patent/SG11201610812WA/en unknown
- 2016-12-16 EP EP16875757.3A patent/EP3390443A4/en active Pending
- 2016-12-16 TW TW110149330A patent/TW202231662A/en unknown
- 2016-12-16 MX MX2018007145A patent/MX2018007145A/en unknown
- 2016-12-16 EA EA201891420A patent/EA201891420A1/en unknown
- 2016-12-16 TW TW106129765A patent/TWI749057B/en active
- 2016-12-16 TW TW105141729A patent/TWI605057B/en active
- 2016-12-16 CN CN201680072782.7A patent/CN108473562B/en active Active
- 2016-12-16 CN CN202210678733.5A patent/CN115028721A/en active Pending
- 2016-12-16 JP JP2016244254A patent/JP6142069B1/en active Active
- 2016-12-16 KR KR1020177003241A patent/KR101820637B1/en active IP Right Grant
- 2016-12-16 AR ARP160103887A patent/AR107078A1/en unknown
- 2016-12-16 AU AU2016372934A patent/AU2016372934B2/en active Active
- 2016-12-16 KR KR1020237005092A patent/KR20230027321A/en not_active IP Right Cessation
2017
- 2017-05-08 JP JP2017092151A patent/JP7053164B2/en active Active
2018
- 2018-06-14 PH PH12018501280A patent/PH12018501280A1/en unknown
- 2018-10-29 HK HK18113798.7A patent/HK1254755A1/en unknown
2022
- 2022-03-31 JP JP2022058710A patent/JP2022097485A/en active Pending
2023
- 2023-11-29 JP JP2023201204A patent/JP2024023427A/en active Pending

Also Published As

Publication number	Publication date
TW202231662A (en)	2022-08-16
CA3002422C (en)	2024-04-16
EP3390443A1 (en)	2018-10-24
BR112018011073A2 (en)	2018-11-21
KR102501335B1 (en)	2023-02-17
TW201808992A (en)	2018-03-16
CA3002422A1 (en)	2017-06-22
MX2018007145A (en)	2018-08-15
HK1254755A1 (en)	2019-07-26
KR20180085711A (en)	2018-07-27
TW201726718A (en)	2017-08-01
TWI605057B (en)	2017-11-11
CN108473562B (en)	2022-06-17
EA201891420A1 (en)	2019-02-28
JP6142069B1 (en)	2017-06-07
WO2017104783A1 (en)	2017-06-22
RU2018125431A (en)	2020-01-20
KR101820637B1 (en)	2018-01-19
SG11201610812WA (en)	2017-07-28
AU2016372934B2 (en)	2023-10-05
JP2017112997A (en)	2017-06-29
JP2017148069A (en)	2017-08-31
JP2024023427A (en)	2024-02-21
CN115028721A (en)	2022-09-09
KR20170085028A (en)	2017-07-21
AU2016372934A1 (en)	2018-05-10
RU2018125431A3 (en)	2020-07-06
JP7053164B2 (en)	2022-04-12
TWI749057B (en)	2021-12-11
PH12018501280A1 (en)	2019-01-28
MY189425A (en)	2022-02-10
KR20230027321A (en)	2023-02-27
CN108473562A (en)	2018-08-31
EP3390443A4 (en)	2019-11-13
JP2022097485A (en)	2022-06-30
AR107078A1 (en)	2018-03-21
KR20240058997A (en)	2024-05-03

Publication	Publication Date	Title
IL278014A (en)	2020-11-30	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
HK1254755A1 (en)	2019-07-26	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL264590A (en)	2019-02-28	Fc region containing polypeptides and uses thereof
HK1246312A1 (en)	2018-09-07	Anti-ceacam6 antibodies and uses thereof
IL258397A (en)	2018-05-31	Anti-age antibodies and methods of use thereof
HK1246321A1 (en)	2018-09-07	Glp and immunoglobulin hybrid fc fused polypeptide and use thereof
SG11201705585QA (en)	2018-05-30	Anti-myostatin antibodies and methods of use
SG11201709573YA (en)	2017-12-28	Specific modification of antibody with igg-binding peptide
IL265290A (en)	2019-05-30	Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use
EP3137505A4 (en)	2017-11-29	Combination of lenalidomide and polypeptide construct, and uses thereof
HK1258166A1 (en)	2019-11-08	Recombinant igg fc multimers
SG11201606597QA (en)	2016-09-29	Multimeric fc proteins
IL284291A (en)	2021-07-29	Humanized anti-acth antibodies and use thereof
EP3394098A4 (en)	2019-11-13	Anti-myostatin antibodies and methods of use
DK3197472T3 (en)	2021-10-18	RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI
SG11201606596PA (en)	2016-09-29	Multimeric fc proteins
ZA201804328B (en)	2022-12-21	Tetravalent anti-psgl-1 antibodies and uses thereof
PL3110447T3 (en)	2020-10-19	Anti-egfr antibody and uses of same
PT3096784T (en)	2020-01-21	Peptides, devices, and methods for the detection of anaplasma antibodies
HK1244534A1 (en)	2018-08-10	Recombinant borrelia proteins and methods of use thereof
SG11201702539UA (en)	2017-04-27	Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorption material
HK1252350A1 (en)	2019-05-24	Mrka polypeptides, antibodies, and uses thereof
TH1701003441A (en)	2021-01-25	Antimyostatin antibodies, polypeptide containing varian Fc regions and methods of application.
GB201504211D0 (en)	2015-04-29	Use of peptides